Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients
Author:
Funder
Merck Serono
National Multiple Sclerosis Society
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,Neurology
Link
http://link.springer.com/article/10.1007/s00415-018-9050-1/fulltext.html
Reference23 articles.
1. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46(4):907–911
2. Stuve O et al (2004) Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. Mult Scler 10(Suppl 1):S58–S61
3. Montalban X et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376(3):209–220
4. Hauser SL et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234
5. Vermersch P, Stojkovic T, de Seze J (2005) Mycophenolate mofetil and neurological diseases. Lupus 14(Suppl 1):s42–s5
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Determining Effectiveness of “Off-Label Therapies” for Multiple Sclerosis in a Real-World Setting;Annals of Indian Academy of Neurology;2024-05
2. Rationale for off-label treatments use in primary progressive multiple sclerosis: A review of the literature;Revue Neurologique;2022-11
3. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure;Frontiers in Neurology;2022-03-31
4. Safety and efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein‐immunoglobulin G‐associated disorder among adults: A meta‐analysis;Clinical and Experimental Neuroimmunology;2021-08-26
5. Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 −106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients;Pharmacogenomics and Personalized Medicine;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3